Bank of America buys 87,118 Medifast shares for its portfolio

Published on 10/06/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bank of America bought 87,118 shares on October 3, 2026. Medifast stock costs EUR 10.42 on October 6, 2026 after EUR 10.40, plus 0.19 percent.

MED, US58470H1014, Illustration mit AI erstellt.

Medifast (ISIN US58470H1014) was trading at EUR 10.42 at Lang & Schwarz on October 6, 2026 at 10:38 a.m. CEST, plus 0.19 percent versus the prior close of EUR 10.40. MarketBeat reported on October 3, 2026 that Bank of America purchased 87,118 Medifast shares valued at USD 924,000.

Bank of America takes a stake

The filing gave Bank of America a 0.78 percent position in Medifast, while institutional investors collectively owned 95.51 percent of the company. MarketBeat also reported that the latest filing showed a USD 12.00 consensus price target and an average Reduce rating.

The institutional purchase arrives as Medifast reshapes its weight-management business around OPTAVIA and a broader metabolic-health strategy. The company remains listed on the New York Stock Exchange under the ticker MED, according to the MarketBeat company profile.

Second-quarter sales still contract

According to Zacks on September 2, 2026, revenue in the second quarter of 2026 fell 27.60 percent year over year to USD 76.40 million from USD 105.60 million. The loss per share was USD 0.28, narrower than the USD 0.67 consensus loss and below the USD 0.22 profit reported for the second quarter of 2025.

The operating picture contains one clear counterpoint. Average revenue per active earning coach rose 41.00 percent year over year to USD 6,529 from USD 4,630, even as the active coach count fell 48.70 percent to 11,700 from 22,800.

Guidance points to a difficult year

Medifast expects third-quarter 2026 revenue of USD 60.00 million to USD 80.00 million and a loss per share of USD 0.15 to USD 0.65, excluding one-time Catalyst costs. For fiscal year 2026, the company reaffirmed revenue guidance of USD 270.00 million to USD 300.00 million and expects a loss per share of USD 0.25 to USD 1.75.

The second-quarter gross margin was 69.90 percent, down from 72.60 percent a year earlier, while the operating loss widened to USD 4.30 million from USD 1.10 million. Management expects a return to profitability beginning in the fourth quarter of 2026, making coach productivity and new-product adoption the key operating tests.

MED quote and market value

Medifast's market capitalization was USD 129.8 million as of October 5, 2026. The NYSE stock's one-year range was USD 9.22 to USD 14.15, with the current euro quotation reflecting a separate Lang & Schwarz trading venue.

At Lang & Schwarz, Medifast was trading at EUR 10.42 on October 6, 2026 at 10:38 a.m. CEST, plus 0.19 percent versus the prior close of EUR 10.40. The quote remains an intraday indication rather than a closing price.